

22 December 2016

The Hon Paul Green MLC
Chair, Legislative Council Select Committee on
off-protocol prescribing of chemotherapy in NSW

Attention Merrin Thompson
chemotherapyinquiry@parliament.nsw.gov.au

Dear Mr Green

**Clarification of matters raised in the Select Committee's hearing on Tuesday
29 November 2016**

The members of the section 122 Inquiry have carefully considered the transcript of the hearing, to which we have made several corrections. To ensure the accuracy of our evidence to the Select Committee, we have also had further recourse to the material that was provided to our Inquiry. We wish to clarify our evidence to the Select Committee in two respects.


Whether anyone other than Dr Grygiel gave evidence to the section 122 Inquiry that Dr Grygiel's practice of prescribing a flat dose of 100 mg carboplatin had been raised with anyone other than Dr Grygiel

Mr Jeremy Buckingham asked several questions about the section 122 Inquiry's response to the Select Committee's supplementary questions on this issue, in particular that two people had given evidence a pharmacist had raised the issue with a senior clinician. As reported on page 15 of the transcript of the hearing, I confirmed The Hon Greg Pearce's comment that this was "hearsay on hearsay". The members of the section 122 Inquiry wish to clarify that one of the two people who gave the evidence to the section 122 Inquiry was the person who had raised the matter with the senior clinician.

Sequence of interviewing senior clinicians

As reported on page 16 of the transcript, the members of the section 122 Inquiry responded to questions from Mr Buckingham that related to the evidence Dr Grygiel gave to the Select Committee, indicating that Dr Stephen Cooper and Dr David Dalley were aware of his prescribing practice. Mr Buckingham asked whether the Inquiry had followed this matter up with Dr Dalley. Dr Curtis indicated the section 122 Inquiry had interviewed Dr Dalley after Dr Grygiel and that Dr Dalley denied knowledge of Dr Grygiel's practice. The members of the section 122 Inquiry confirm that Dr Dalley denied knowledge of Dr Grygiel's practice, but wish to clarify that Dr Dalley was interviewed before Dr Grygiel.

Yours sincerely,



Professor David Currow
Chief Cancer Officer, NSW
Chief Executive Officer, Cancer Institute NSW

Cancer Institute NSW

ABN 48 538 442 594

Level 9, 8 Central Avenue, Australian Technology Park, Eveleigh NSW 2015

PO Box 41, Alexandria, NSW 1435

t +61 (0)2 8374 5600 f +61 (0)2 8374 3600 e information@cancerinstitute.org.au

www.cancerinstitute.org.au